Business

The FINANCIAL -- With numerous marketing authorisations for medicines and product launches in 2014, the research-driven pharmaceutical company Boehringer Ingelheim is now positioned for future growth. "After a challenging 2014, the focus for us now is on launching numerous additional new products and on our profitability," said Professor Andreas Barner, Chairman of the Board of Managing Directors ...

More Articles ...

More Articles ...

The FINANCIAL -- Astellas Pharma Inc. and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, on April 22 announced an exclusive research and ...